UNH · Company research
UNITEDHEALTH GROUP INCORPORATED (Delaware) (UNH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
61records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| The Zacks Analyst Blog Highlights UnitedHealth, ServiceNow, 3M and Coffee | Zacks Equity Research analysts published featured research reports on four stocks. UnitedHealth received a Neutral rating despite strong Q3 earnings and diversified operations, citing regulatory scrutiny and premium valuation concerns. ServiceNow faces software competition and AI spending risks but benefits from enterprise digitization trends. 3M outperformed its industry with strong momentum in Safety and Industrial segments, though retail weakness and high debt remain concerns. Coffee Holding, a microcap, showed growth potential from acquisitions and improved profitability, but faces commodity price volatility and sustainability concerns. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | bullish | 0.25 | 1 |
| Top Research Reports for UnitedHealth, ServiceNow & 3M | Zacks Research Daily presents hand-picked analysis of 12 major stocks. UnitedHealth Group receives a Neutral rating despite strong Q3 earnings, citing regulatory scrutiny and premium valuation. ServiceNow faces software competition but benefits from AI adoption and enterprise digitization. 3M outperforms its industry with strong Safety and Industrial momentum, though consumer discretionary weakness persists. Additional coverage includes Otis, Brown & Brown, Ensign Group, Glaukos, Domino's, CarMax, Par Pacific, MP Materials, and Lennar. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.571 | 1 |
| UnitedHealth's Q3 Margins Improve, But Membership Falls: Time to Buy? | UnitedHealth Group reported Q3 adjusted earnings of $4.69 per share, beating estimates by 13.9% with a 60.6% year-over-year increase. The company raised its 2026 EPS outlook to at least $20.50, driven by improved margins and lower medical costs. However, membership declined to 48.3 million from 50.1 million, raising questions about long-term sustainability. Optum also showed strong recovery with margins expanding to 5.6%. The stock carries a Zacks Rank #2 (Buy) rating with valuation below historical medians. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| 3 Companies Raising Guidance This Earnings Season | BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| 3 Companies Raising Guidance This Earnings Season | BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge | With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge | With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| VOO is up 0.1% today, on UNH stock price movement - Quiver Quantitative | VOO is up 0.1% today, on UNH stock price movement Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 15, 2026 | neutral | 0 | 0.6 |
| Can UNH's Focus on Special Needs Plans Strengthen Medicare Growth? | UnitedHealth Group is prioritizing Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs) for 2027 to drive targeted Medicare Advantage growth. UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, with at least 69% of its Medicare Advantage members in four-star or higher rated plans. The company faces competition from Humana and Centene, which are also expanding specialized Medicare Advantage offerings. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.667 | 1 |
| Can UNH's Focus on Special Needs Plans Strengthen Medicare Growth? | UnitedHealth Group is prioritizing Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs) for 2027 to drive targeted Medicare Advantage growth. UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, with at least 69% of its Medicare Advantage members in four-star or higher rated plans. The company faces competition from Humana and Centene, which are also expanding specialized Medicare Advantage offerings. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.667 | 1 |
| What Happened With UnitedHealth Stock This Week? - Yahoo Finance | What Happened With UnitedHealth Stock This Week? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Centene's Gold Card Push Could Ease Costs - But Will Savings Follow? | Centene Corporation will launch its National Performance-Based Gold Card Program nationwide in November 2026, covering over 160,000 providers and allowing qualifying providers to bypass prior authorization for eligible outpatient services. The initiative aims to reduce administrative burden and processing costs while maintaining clinical oversight. Centene trades at 13.13x forward earnings with 2026 EPS estimated to grow 135.1% to $4.89, though the stock carries a Zacks Rank #4 (Sell) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.667 | 1 |
| UNH Q3 Earnings Call Highlights 2027 Growth and Margin Recovery | UnitedHealth Group raised its 2026 adjusted EPS guidance to at least $20.50 and signaled a return to sustainable earnings growth in 2027. The company reported strong Q3 results with adjusted earnings of $4.69 per share exceeding expectations. While commercial medical costs remain elevated and Medicaid funding gaps persist, Optum Health's earnings rebound and AI expansion initiatives support the recovery outlook. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| UNH Q3 Earnings Call Highlights 2027 Growth and Margin Recovery | UnitedHealth Group raised its 2026 adjusted EPS guidance to at least $20.50 and signaled a return to sustainable earnings growth in 2027. The company reported strong Q3 results with adjusted earnings of $4.69 per share exceeding expectations. While commercial medical costs remain elevated and Medicaid funding gaps persist, Optum Health's earnings rebound and AI expansion initiatives support the recovery outlook. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| UnitedHealth Group (UNH) is a Top-Ranked Momentum Stock: Should You Buy? | UnitedHealth Group (UNH) has been identified as a top-ranked momentum stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company received upward earnings estimate revisions, with the consensus estimate increasing to $19.85 per share for fiscal 2026, and has demonstrated a strong average earnings surprise of +14%. The stock is recommended for momentum investors seeking exposure to the healthcare sector. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| UnitedHealth Group (UNH) is a Top-Ranked Momentum Stock: Should You Buy? | UnitedHealth Group (UNH) has been identified as a top-ranked momentum stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company received upward earnings estimate revisions, with the consensus estimate increasing to $19.85 per share for fiscal 2026, and has demonstrated a strong average earnings surprise of +14%. The stock is recommended for momentum investors seeking exposure to the healthcare sector. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| UnitedHealth Stock Forecast: TD Cowen Stays Cautious Even as Mizuho Names UNH a Top Pick - TipRanks | UnitedHealth Stock Forecast: TD Cowen Stays Cautious Even as Mizuho Names UNH a Top Pick TipRanks | View source ↗ | TipRanks | Oct 14, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Stock Rallies After Q3 Profit And Revenue Beat - Yahoo Finance | UnitedHealth Stock Rallies After Q3 Profit And Revenue Beat Yahoo Finance UnitedHealth: Huge Earnings Surprise (NYSE:UNH) Seeking Alpha UnitedHealth Stock Moves Higher: What's Happening? Benzinga | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? | UnitedHealth and Johnson & Johnson both raised full-year guidance after Q3 earnings, but with contrasting performance. UnitedHealth beat expectations with 60% YoY EPS growth driven by improved medical cost management, while J&J saw earnings decline 7.5% YoY despite pharmaceutical growth offsetting weak MedTech performance. UnitedHealth is recommended as the better buy due to stronger earnings momentum, lower valuation (19X vs 23X forward earnings), and higher dividend yield (2.45% vs 2%). | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? | UnitedHealth and Johnson & Johnson both raised full-year guidance after Q3 earnings, but with contrasting performance. UnitedHealth beat expectations with 60% YoY EPS growth driven by improved medical cost management, while J&J saw earnings decline 7.5% YoY despite pharmaceutical growth offsetting weak MedTech performance. UnitedHealth is recommended as the better buy due to stronger earnings momentum, lower valuation (19X vs 23X forward earnings), and higher dividend yield (2.45% vs 2%). | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| Oscar Health Raises 2026 Operating Earnings Outlook as Margins Improve | Oscar Health raised its 2026 operating earnings guidance to $500M-$700M from $250M-$450M, driven by improved medical loss ratios (75% from 83%), disciplined pricing, and technology-driven expense efficiency. However, the company faces headwinds in the second half including 2%-4% monthly churn, rising medical costs, and open-enrollment spending. Revenue guidance remained unchanged at $18.7B-$19B. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Oscar Health Raises 2026 Operating Earnings Outlook as Margins Improve | Oscar Health raised its 2026 operating earnings guidance to $500M-$700M from $250M-$450M, driven by improved medical loss ratios (75% from 83%), disciplined pricing, and technology-driven expense efficiency. However, the company faces headwinds in the second half including 2%-4% monthly churn, rising medical costs, and open-enrollment spending. Revenue guidance remained unchanged at $18.7B-$19B. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Is Oscar Health Stock a Buy as Growth Surges but Valuation Stays Rich? | Oscar Health (OSCR) demonstrates impressive growth with Q2 revenues surging 70.4% to $4.9 billion and membership jumping 46.2% to 2.96 million, significantly outpacing a contracting ACA market. However, the stock trades at a premium valuation of 5.5X tangible book value versus the sub-industry's 1.2X, leaving limited room for disappointment. Execution risks include rising churn rates, increasing medical costs, and favorable reserve items that may not repeat, though the company maintains a strong capital base of $10.2 billion. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Is Oscar Health Stock a Buy as Growth Surges but Valuation Stays Rich? | Oscar Health (OSCR) demonstrates impressive growth with Q2 revenues surging 70.4% to $4.9 billion and membership jumping 46.2% to 2.96 million, significantly outpacing a contracting ACA market. However, the stock trades at a premium valuation of 5.5X tangible book value versus the sub-industry's 1.2X, leaving limited room for disappointment. Execution risks include rising churn rates, increasing medical costs, and favorable reserve items that may not repeat, though the company maintains a strong capital base of $10.2 billion. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going? | Oscar Health (OSCR) shares have gained 14.9% over three months, driven by 46.2% year-over-year membership growth to 2.96 million members and improved medical economics. The company's medical loss ratio improved to 75% from 83%, while SG&A expenses fell to 14.7% from 17.2%, supported by technology efficiencies. However, the stock faces headwinds from ACA market contraction and a valuation that already reflects higher expectations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going? | Oscar Health (OSCR) shares have gained 14.9% over three months, driven by 46.2% year-over-year membership growth to 2.96 million members and improved medical economics. The company's medical loss ratio improved to 75% from 83%, while SG&A expenses fell to 14.7% from 17.2%, supported by technology efficiencies. However, the stock faces headwinds from ACA market contraction and a valuation that already reflects higher expectations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading | Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%. Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations. | View source ↗ | The Motley Fool | Oct 13, 2026 | bearish | -0.192 | 1 |
| Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading | Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%. Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations. | View source ↗ | The Motley Fool | Oct 13, 2026 | bearish | -0.192 | 1 |
| UNH Tops Q3 Earnings on Lower Medical Costs, Raises '26 Outlook | UnitedHealth Group (UNH) reported Q3 2026 adjusted EPS of $4.69, beating estimates by 13.8% with a 60.6% year-over-year increase. The company improved its medical care ratio to 88.4% and raised its 2026 adjusted EPS guidance to at least $20.50. Strong performance from Optum Insight and Optum Rx offset weakness in Optum Health and declining memberships. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| UNH Tops Q3 Earnings on Lower Medical Costs, Raises '26 Outlook | UnitedHealth Group (UNH) reported Q3 2026 adjusted EPS of $4.69, beating estimates by 13.8% with a 60.6% year-over-year increase. The company improved its medical care ratio to 88.4% and raised its 2026 adjusted EPS guidance to at least $20.50. Strong performance from Optum Insight and Optum Rx offset weakness in Optum Health and declining memberships. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| UnitedHealth Group Stock Gains on Strong Earnings - Investopedia | UnitedHealth Group Stock Gains on Strong Earnings Investopedia | View source ↗ | Investopedia | Oct 13, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Climbs As Earnings, Medical Costs Beat Forecasts - Investor's Business Daily | UnitedHealth Climbs As Earnings, Medical Costs Beat Forecasts Investor's Business Daily | View source ↗ | Investor's Business Daily | Oct 13, 2026 | neutral | 0 | 0.6 |
| 4 stocks to watch on Tuesday: WFC, UNH, DPZ, and JPM (SPX:) - Seeking Alpha | 4 stocks to watch on Tuesday: WFC, UNH, DPZ, and JPM (SPX:) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| Stocks making the biggest moves premarket: JPMorgan Chase, Micron, UnitedHealth & more - CNBC | Stocks making the biggest moves premarket: JPMorgan Chase, Micron, UnitedHealth & more CNBC | View source ↗ | CNBC | Oct 13, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Group (UNH) Q3 Earnings and Revenues Top Estimates | UnitedHealth Group reported Q3 2026 earnings of $4.69 per share, beating consensus estimates of $4.12 and representing a 13.84% surprise. The company posted revenues of $112.69 billion, slightly exceeding expectations. With a Zacks Rank #2 (Buy) rating, UnitedHealth has outperformed the S&P 500 by 0.6% year-to-date. However, the Medical - HMOs industry ranks in the bottom 24% of Zacks industries, which could impact future performance. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| UnitedHealth Group (UNH) Q3 Earnings and Revenues Top Estimates | UnitedHealth Group reported Q3 2026 earnings of $4.69 per share, beating consensus estimates of $4.12 and representing a 13.84% surprise. The company posted revenues of $112.69 billion, slightly exceeding expectations. With a Zacks Rank #2 (Buy) rating, UnitedHealth has outperformed the S&P 500 by 0.6% year-to-date. However, the Medical - HMOs industry ranks in the bottom 24% of Zacks industries, which could impact future performance. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| UnitedHealth: Q3 Earnings Snapshot - Yahoo Finance | UnitedHealth: Q3 Earnings Snapshot Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs - CNBC | UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs CNBC | View source ↗ | CNBC | Oct 13, 2026 | neutral | 0 | 0.6 |
| UnitedHealth shares are doing something unusual ahead of earnings - CNBC | UnitedHealth shares are doing something unusual ahead of earnings CNBC | View source ↗ | CNBC | Oct 12, 2026 | neutral | 0 | 0.6 |
| Middle East Tensions Rattle Markets | Markets face a volatile week with Middle East tensions following Houthi attacks on Saudi Arabia's airport, pushing oil prices higher. Key economic data including September CPI and PPI inflation reports are expected this week, with CPI anticipated to rise 30 basis points to +3.7%. Q3 earnings season kicks off with major banks and healthcare companies reporting, including JPMorgan, Citigroup, Wells Fargo, Goldman Sachs, Johnson & Johnson, and UnitedHealthcare. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0.04 | 1 |
| Big Week of Data: Inflation & Q3 Earnings | Houthi attacks on Saudi Arabia's Riyadh airport over the weekend killed 14 and injured over 300, sending oil prices higher (WTI at $93/bbl, Brent at $106/bbl). The market faces a busy week with Q3 earnings from major banks and healthcare companies, alongside critical CPI and PPI inflation reports expected to show inflation ticking higher. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0.04 | 1 |
| Here’s How Much Traders See UnitedHealth Stock Moving After Earnings - Investopedia | Here’s How Much Traders See UnitedHealth Stock Moving After Earnings Investopedia | View source ↗ | Investopedia | Oct 12, 2026 | neutral | 0 | 0.6 |
| Estimates Keep Rising as Q3 Earnings Season Takes Center Stage | Q3 earnings season begins with JPMorgan, Citigroup, and others reporting results. S&P 500 earnings are expected to grow 24.3% YoY with positive revisions across 7 of 16 sectors. However, banks face pressure from rising Treasury yields impacting net interest margins and deal flow. Of 19 companies that have reported, 78.9% beat EPS estimates, though results are heavily skewed by Micron's exceptional performance. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.222 | 1 |
| UnitedHealth Group (UNH) Beats Stock Market Upswing: What Investors Need to Know | UnitedHealth Group closed at $378.81, up 2.12% and outperforming the S&P 500's 0.6% gain. Despite a 4.46% loss over the past month, the company holds a Zacks Rank #2 (Buy) rating. UNH is expected to report Q3 earnings on October 13, 2026, with projected EPS of $4.12 (41.1% growth YoY) and revenue of $111.38 billion (down 1.57% YoY). The stock trades at a Forward P/E of 18.69, below the industry average of 20.83. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| UnitedHealth vs. Humana: Which Healthcare Giant Has the Edge? | UnitedHealth Group (UNH) and Humana (HUM) are compared as major players in U.S. managed healthcare. UNH benefits from its diversified Optum platform, improving Medicare Advantage profitability, and $1.5B AI investments, while HUM shows strong Medicare Advantage membership growth of 23.8% but faces margin pressures from rising benefit costs. UNH is rated as the more compelling investment with a Zacks Rank #2 (Buy) versus HUM's Rank #3 (Hold), offering 28.1% upside potential compared to HUM's 7.7%. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.5 | 1 |
| UnitedHealth Group (UNH) Stock Still Looks Undervalued After Medicare Reset - Simply Wall Street | UnitedHealth Group (UNH) Stock Still Looks Undervalued After Medicare Reset Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Group (UNH) Registers a Bigger Fall Than the Market: Important Facts to Note | UnitedHealth Group closed down 1.42% on October 8, 2026, underperforming the S&P 500's 0.47% loss. The stock has declined 4.35% over the past month. Upcoming earnings on October 13 are expected to show 41.1% EPS growth to $4.12, though revenue is projected to decline 1.57% to $111.38 billion. UNH holds a Zacks Rank #2 (Buy) with a Forward P/E of 18.94, trading at a discount to its industry average of 21.09. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| CVS Health Trades at a Discount to Industry: How to Play the Stock? | CVS Health demonstrates attractive valuation and improving business performance, with Aetna's margin recovery gaining momentum and pharmacy segment showing strong prescription volume growth. However, 340B program pressures and expected Caremark membership declines pose near-term challenges. The stock trades at a discount to peers and has outperformed its industry, though technical indicators suggest weaker momentum. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Dear UnitedHealth Stock Fans, Mark Your Calendars for October 13 - Barchart.com | Dear UnitedHealth Stock Fans, Mark Your Calendars for October 13 Barchart.com | View source ↗ | Barchart.com | Oct 8, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Gears Up for Q3 Earnings: Should Investors Buy the Stock? - TradingView | UnitedHealth Gears Up for Q3 Earnings: Should Investors Buy the Stock? TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Gears Up for Q3 Earnings: Should Investors Buy the Stock? | UnitedHealth Group is expected to report Q3 2026 earnings on October 13, 2026, with projected EPS growth of 41.1% to $4.12 per share, despite a 1.6% revenue decline to $111.38 billion. The company faces headwinds from declining memberships across commercial, Medicare Advantage, and Medicaid segments, but improved medical cost management and operational restructuring are expected to support margin expansion. UnitedHealth trades below its historical valuation median at 17.15X forward earnings, positioning it for potential recovery. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.333 | 1 |
| UnitedHealth Group (UNH) Stock Looks Like A Bargain At This Price - Yahoo Finance UK | UnitedHealth Group (UNH) Stock Looks Like A Bargain At This Price Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 8, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance | UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know | UnitedHealth Group (UNH) has attracted investor attention despite a -4.4% return over the past month. The company is expected to report 41.1% earnings growth for the current quarter and 21.4% for the fiscal year, with a Zacks Rank #2 (Buy) rating. UnitedHealth trades at a discount to peers with a Value Style Score of A, though revenue growth remains modest at -0.2% for the current fiscal year. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans - Stocktwits | CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Stock Testing Key Support as Earnings Loom - Schaeffer's Investment Research | UnitedHealth Stock Testing Key Support as Earnings Loom Schaeffer's Investment Research | View source ↗ | Schaeffer's Investment Research | Oct 8, 2026 | neutral | 0 | 0.6 |
| Why Did CSX, PENG, UNH Stocks Ascend To 52-Week Highs Today? - Stocktwits | Why Did CSX, PENG, UNH Stocks Ascend To 52-Week Highs Today? Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| UnitedHealth: The Upside Is Gone (NYSE:UNH) - Seeking Alpha | UnitedHealth: The Upside Is Gone (NYSE:UNH) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 6, 2026 | neutral | 0 | 0.6 |
| Quarterly pay gives UnitedHealth (UNH) director Garcia 103 shares and 155 deferred stock awards. - Stock Titan | Quarterly pay gives UnitedHealth (UNH) director Garcia 103 shares and 155 deferred stock awards. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Group: Getting Cheaper And Cheaper (NYSE:UNH) - Seeking Alpha | UnitedHealth Group: Getting Cheaper And Cheaper (NYSE:UNH) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 5, 2026 | neutral | 0 | 0.6 |
| UnitedHealth Beat Q2 by 30%. Six Weeks Later the Stock Gave It All Back - TIKR.com | UnitedHealth Beat Q2 by 30%. Six Weeks Later the Stock Gave It All Back TIKR.com | View source ↗ | TIKR.com | Aug 31, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.